CanaQuest is a clinical-stage life sciences company focused on targeted cannabinoid therapeutics for the central nervous system. The R & D involving pre-clinical trials was completed by Dr. Steven Laviolette, a professor, and neuroscientist at Western University. This research provides the science for drug candidate CQ-001 a formulation of “CBD” + essential fatty acids (the over-the-counter (OTC) version is called Mentanine®).